Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Cellular Oncology
Erschienen in: Cellular Oncology 6/2012

01.12.2012 | Original Papers

High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients

verfasst von: Jong-Rung Tsai, Hui-Min Wang, Po-Len Liu, Yung-Hsiang Chen, Ming-Chan Yang, Shah-Hwa Chou, Yu-Jen Cheng, Wei-Hsian Yin, Jhi-Jhu Hwang, Inn-Wen Chong

Erschienen in: Cellular Oncology | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Heme oxygenase-1 (HO-1), a rate-limiting enzyme in heme catabolism, is known to play a role in the protection of cells against oxidative stress, inflammation, anomalous proliferation and apoptosis. As yet, the role of HO-1 expression in non-small cell lung cancer (NSCLC) development and metastasis remains unclear and insufficient data are available regarding its impact on the prognosis of NSCLC patients.

Methods

Seventy NSCLC patients who underwent surgical resection were included in this HO-1 expression study and, concomitantly, clinical parameters were collected. Two lung adenocarcinoma cell lines (A549 and H441) were used to assess both invasive and migratory parameters in vitro.

Results

NSCLC patients with a high HO-1 expression ratio (tumor tissue/normal tissue) (> 1) exhibited a significantly poorer prognosis and a higher metastatic rate compared to those with a low HO-1 expression ratio (p < 0.05). The invasive and migratory abilities of A549 and H441 cells significantly increased after exogenous HO-1 over-expression and significantly decreased after siRNA-mediated HO-1 expression silencing. HO-1 up- and down-regulation also positively correlated with the expression of metastasis-associated proteins EGFR, CD147 and MMP-9. In addition, we found that HO-1 expression can be inhibited by PI3K and AKT inhibitors, but not by MAPK inhibitors.

Conclusions

HO-1 is a poor prognostic NSCLC predictor and its over-expression may increase the metastatic potential of NSCLC. Based on our findings and those of others, HO-1 may be considered as a novel NSCLC therapeutic target.
Literatur
1.
M.D. Maines, Heme oxygenase: Function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J. 2, 2557–2568 (1988)PubMed
2.
J.C. Becker, H. Fukui, Y. Imai, A. Sekikawa, T. Kimura, H. Yamagishi et al., Colonic expression of heme oxygenase-1 is associated with a better long-term survival in patients with colorectal cancer. Scand. J. Gastroenterol. 42, 852–858 (2007)PubMedCrossRef
3.
M.D. Maines, The heme oxygenase system: A regulator of second messenger gases. Annu. Rev. Pharmacol. Toxicol. 37, 517–554 (1997)PubMedCrossRef
4.
W. Durante, Heme oxygenase-1 in growth control and its clinical application to vascular disease. J. Cell. Physiol. 195, 373–382 (2003)PubMedCrossRef
5.
D. Morse, A.M. Choi, Heme oxygenase-1: The “emerging molecule” has arrived. American journal of respiratory cell and molecular biology 27, 8–16 (2002)PubMed
6.
S.S. Lee, S.F. Yang, C.H. Tsai, M.C. Chou, M.Y. Chou, Y.C. Chang, Upregulation of heme oxygenase-1 expression in areca-quid-chewing-associated oral squamous cell carcinoma. Journal of the Formosan Medical Association Taiwan yi zhi. 107, 355–363 (2008)PubMedCrossRef
7.
S. Ishikawa, S. Tamaki, M. Ohata, K. Arihara, M. Itoh, Heme induces DNA damage and hyperproliferation of colonic epithelial cells via hydrogen peroxide produced by heme oxygenase: A possible mechanism of heme-induced colon cancer. Mol. Nutr. Food. Res. 54, 1182–1191 (2010)PubMed
8.
T. Ishikawa, N. Yoshida, H. Higashihara, M. Inoue, K. Uchiyama, T. Takagi et al., Different effects of constitutive nitric oxide synthase and heme oxygenase on pulmonary or liver metastasis of colon cancer in mice. Clinical & experimental metastasis. 20, 445–450 (2003)CrossRef
9.
G. Gueron, A. De Siervi, M. Ferrando, M. Salierno, P. De Luca, B. Elguero et al., Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer cells. Mol. Cancer Res. 7, 1745–1755 (2009)PubMedCrossRef
10.
M.A. Alaoui-Jamali, T.A. Bismar, A. Gupta, W.A. Szarek, J. Su, W. Song et al., A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer. Cancer Res. 69, 8017–8024 (2009)PubMedCrossRef
11.
H.R. Kim, S. Kim, E.J. Kim, J.H. Park, S.H. Yang, E.T. Jeong et al., Suppression of Nrf2-driven heme oxygenase-1 enhances the chemosensitivity of lung cancer A549 cells toward cisplatin. Lung Cancer 60, 47–56 (2008)PubMedCrossRef
12.
K. Hirai, T. Sasahira, H. Ohmori, K. Fujii, H. Kuniyasu, Inhibition of heme oxygenase-1 by zinc protoporphyrin IX reduces tumor growth of LL/2 lung cancer in C57BL mice. Int. J. Cancer 120, 500–505 (2007)PubMedCrossRef
13.
P. Boschetto, E. Zeni, L. Mazzetti, D. Miotto, N. Lo Cascio, P. Maestrelli et al., Decreased heme-oxygenase (HO)-1 in the macrophages of non-small cell lung cancer. Lung Cancer 59, 192–197 (2008)PubMedCrossRef
14.
M.S. Degese, J.E. Mendizabal, N.A. Gandini, J.S. Gutkind, A. Molinolo, S.M. Hewitt et al., Expression of heme oxygenase-1 in non-small cell lung cancer (NSCLC) and its correlation with clinical data. Lung Cancer 77, 168–175 (2012)PubMedCrossRef
15.
A. Jozkowicz, H. Was, J. Dulak, Heme oxygenase-1 in tumors: Is it a false friend? Antioxid. Redox. Signal. 9, 2099–2117 (2007)PubMedCrossRef
16.
R.S. Herbst, Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys. 59, 21–26 (2004)PubMedCrossRef
17.
H. Sasaki, H. Yukiue, K. Mizuno, A. Sekimura, A. Konishi, M. Yano et al., Elevated serum epidermal growth factor receptor level is correlated with lymph node metastasis in lung cancer. International journal of clinical oncology/Japan Society of Clinical Oncology. 8, 79–82 (2003)PubMedCrossRef
18.
T. Kanekura, X. Chen, CD147/basigin promotes progression of malignant melanoma and other cancers. J. Dermatol. Sci. 57, 149–154 (2010)PubMedCrossRef
19.
J. Xu, H.Y. Xu, Q. Zhang, F. Song, J.L. Jiang, X.M. Yang et al., HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol. Cancer Res. 5, 605–614 (2007)PubMedCrossRef
20.
H. Voigt, C.S. Vetter-Kauczok, D. Schrama, U.B. Hofmann, J.C. Becker, R. Houben, CD147 impacts angiogenesis and metastasis formation. Cancer investigation. 27, 329–333 (2009)PubMedCrossRef
21.
H. Was, J. Dulak, A. Jozkowicz, Heme oxygenase-1 in tumor biology and therapy. Current drug targets. 11, 1551–1570 (2010)PubMedCrossRef
22.
H. Was, T. Cichon, R. Smolarczyk, D. Rudnicka, M. Stopa, C. Chevalier et al., Overexpression of heme oxygenase-1 in murine melanoma: Increased proliferation and viability of tumor cells, decreased survival of mice. Am. J. Pathol. 169, 2181–2198 (2006)PubMedCrossRef
23.
M.H. Tsuji, T. Yanagawa, S. Iwasa, K. Tabuchi, K. Onizawa, S. Bannai et al., Heme oxygenase-1 expression in oral squamous cell carcinoma as involved in lymph node metastasis. Cancer Lett. 138, 53–59 (1999)PubMedCrossRef
24.
M. Sunamura, D.G. Duda, M.H. Ghattas, L. Lozonschi, F. Motoi, J. Yamauchi et al., Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis 6, 15–24 (2003)PubMedCrossRef
25.
P. Boschetto, E. Zeni, L. Mazzetti, D. Miotto, N.L. Cascio, P. Maestrelli et al., Decreased heme-oxygenase (HO)-1 in the macrophages of non-small cell lung cancer. Lung Cancer 59, 192–197 (2008)PubMedCrossRef
26.
C.K. Andreadi, L.M. Howells, P.A. Atherfold, M.M. Manson, Involvement of Nrf2, p38, B-Raf, and nuclear factor-kappaB, but not phosphatidylinositol 3-kinase, in induction of hemeoxygenase-1 by dietary polyphenols. Mol. Pharmacol. 69, 1033–1040 (2006)PubMed
27.
S. Kocanova, E. Buytaert, J.Y. Matroule, J. Piette, J. Golab, P. de Witte et al., Induction of heme-oxygenase 1 requires the p38MAPK and PI3K pathways and suppresses apoptotic cell death following hypericin-mediated photodynamic therapy. Apoptosis 12, 731–741 (2007)PubMedCrossRef
28.
E.J. Joung, M.H. Li, H.G. Lee, N. Somparn, Y.S. Jung, H.K. Na et al., Capsaicin induces heme oxygenase-1 expression in HepG2 cells via activation of PI3K-Nrf2 signaling: NAD(P)H:quinone oxidoreductase as a potential target. Antioxid. Redox. Signal. 9, 2087–2098 (2007)PubMedCrossRef
29.
C.F. Mountain, Revisions in the International System for Staging Lung Cancer. Chest 111, 1710–1717 (1997)PubMedCrossRef
30.
V.K. Sarhadi, H. Wikman, K. Salmenkivi, E. Kuosma, T. Sioris, J. Salo et al., Increased expression of high mobility group A proteins in lung cancer. J. Pathol. 209, 206–212 (2006)PubMedCrossRef
31.
H. Wikman, E. Kettunen, J.K. Seppanen, A. Karjalainen, J. Hollmen, S. Anttila et al., Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene 21, 5804–5813 (2002)PubMedCrossRef
32.
T.C. Wu, Y.H. Chen, H.B. Leu, Y.L. Chen, F.Y. Lin, S.J. Lin et al., Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and −9 in experimental atherosclerosis. Free Radic. Biol. Med. 43, 1508–1522 (2007)PubMedCrossRef
33.
S.J. Lin, I.T. Lee, Y.H. Chen, F.Y. Lin, L.M. Sheu, H.H. Ku et al., Salvianolic acid B attenuates MMP-2 and MMP-9 expression in vivo in apolipoprotein-E-deficient mouse aorta and in vitro in LPS-treated human aortic smooth muscle cells. J. Cell. Biochem. 100, 372–384 (2007)PubMedCrossRef
34.
H.M. Wang, C.C. Chiu, P.F. Wu, C.Y. Chen, Subamolide E from Cinnamomum subavenium induces sub-G1 cell-cycle arrest and caspase-dependent apoptosis and reduces the migration ability of human melanoma cells. J. Agric. Food Chem. 59, 8187–8192 (2011)PubMedCrossRef
35.
F. Shiraishi, L.M. Curtis, L. Truong, K. Poss, G.A. Visner, K. Madsen, H.S. Nick, A. Agarwal, Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. Am J Physiol Renal Physiol 278, F726–F736 (2000)PubMed
36.
A. Albini, R. Benelli, The chemoinvasion assay: A method to assess tumor and endothelial cell invasion and its modulation. Nat. Protoc. 2(504–11) (2007)
37.
S. Tang, K.G. Morgan, C. Parker, J.A. Ware, Requirement for protein kinase C theta for cell cycle progression and formation of actin stress fibers and filopodia in vascular endothelial cells. J. Biol. Chem. 272, 28704–28711 (1997)PubMedCrossRef
38.
G. Wang, E. Reed, Q.Q. Li, Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol. Rep. 12, 955–965 (2004)PubMed
39.
N. Grabinski, K. Bartkowiak, K. Grupp, B. Brandt, K. Pantel, M. Jucker, Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells. Cell. Signal. 23, 1952–1960 (2011)PubMedCrossRef
40.
L. Mansi, E. Viel, E. Curtit, J. Medioni, C. Le Tourneau, Targeting the RAS signalling pathway in cancer therapy. Nat. Rev. Cancer 3, 11–22 (2003)CrossRef
41.
R. Tenhunen, H.S. Marver, R. Schmid, The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc. Natl. Acad. Sci. U. S. A. 61, 748–755 (1968)PubMedCrossRef
42.
K. Doi, T. Akaike, S. Fujii, S. Tanaka, N. Ikebe, T. Beppu et al., Induction of haem oxygenase-1 nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth. Br. J. Cancer 80, 1945–1954 (1999)PubMedCrossRef
43.
E. Hara, K. Takahashi, T. Tominaga, T. Kumabe, T. Kayama, H. Suzuki et al., Expression of heme oxygenase and inducible nitric oxide synthase mRNA in human brain tumors. Biochem. Biophys. Res. Commun. 224, 153–158 (1996)PubMedCrossRef
44.
M.Y. Li, J. Yip, M.K. Hsin, T.S. Mok, Y. Wu, M.J. Underwood et al., Haem oxygenase-1 plays a central role in NNK-mediated lung carcinogenesis. Eur. Respir. J. 32, 911–923 (2008)PubMedCrossRef
45.
H. Kuroda, M. Takeno, S. Murakami, N. Miyazawa, T. Kaneko, Y. Ishigatsubo, Inhibition of heme oxygenase-1 with an epidermal growth factor receptor inhibitor and cisplatin decreases proliferation of lung cancer A549 cells. Lung Cancer 67, 31–36 (2010)PubMedCrossRef
46.
P.L. Liu, J.R. Tsai, A.L. Charles, J.J. Hwang, S.H. Chou, Y.H. Ping et al., Resveratrol inhibits human lung adenocarcinoma cell metastasis by suppressing heme oxygenase 1-mediated nuclear factor-kappaB pathway and subsequently downregulating expression of matrix metalloproteinases. Mol. Nutr. Food Res. 54(2), S196–S204 (2010)PubMedCrossRef
47.
T. Yanagawa, K. Omura, H. Harada, K. Nakaso, S. Iwasa, Y. Koyama et al., Heme oxygenase-1 expression predicts cervical lymph node metastasis of tongue squamous cell carcinomas. Oral oncology. 40, 21–27 (2004)PubMedCrossRef
48.
G. De Palma, P. Mozzoni, O. Acampa, E. Internullo, P. Carbognani, M. Rusca et al., Expression levels of some antioxidant and epidermal growth factor receptor genes in patients with early-stage non-small cell lung cancer. Journal of nucleic acids (2010).
49.
M. Mareel, I. Madani, Tumour-associated host cells participating at invasion and metastasis: Targets for therapy? Acta. chirurgica. Belgica. 106, 635–640 (2006)PubMed
50.
A. Prawan, J.K. Kundu, Y.J. Surh, Molecular basis of heme oxygenase-1 induction: Implications for chemoprevention and chemoprotection. Antioxid. Redox. Signal. 7, 1688–1703 (2005)PubMedCrossRef
51.
J. Alam, C. Wicks, D. Stewart, P. Gong, C. Touchard, S. Otterbein et al., Mechanism of heme oxygenase-1 gene activation by cadmium in MCF-7 mammary epithelial cells. Role of p38 kinase and Nrf2 transcription factor. J. Biol. Chem. 275, 27694–27702 (2000)PubMed
52.
E.H. Kim, D.H. Kim, H.K. Na, Y.J. Surh, Effects of cyclopentenone prostaglandins on the expression of heme oxygenase-1 in MCF-7 cells. Ann. N. Y. Acad. Sci. 1030, 493–500 (2004)PubMedCrossRef
Metadaten
Titel
High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients
verfasst von
Jong-Rung Tsai
Hui-Min Wang
Po-Len Liu
Yung-Hsiang Chen
Ming-Chan Yang
Shah-Hwa Chou
Yu-Jen Cheng
Wei-Hsian Yin
Jhi-Jhu Hwang
Inn-Wen Chong
Publikationsdatum
01.12.2012
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 6/2012
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-012-0105-5

Weitere Artikel der Ausgabe 6/2012

Cellular Oncology 6/2012 Zur Ausgabe

Original Paper

Disulfide-stabilized diabody antiCD19/antiCD3 exceeds its parental antibody in tumor-targeting activity

Original Paper

HIF-1α and NOTCH signaling in ductal and lobular carcinomas of the breast

Original Paper

Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development

Review

Interpretation of interlocking key issues of cancer stem cells in malignant solid tumors

Original Paper

EGFR status and KRAS/BRAF mutations in intestinal-type sinonasal adenocarcinomas

Original Paper

CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Zielgerichtete Therapie Leitthema

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …